SBP GROUP (01177) reached an exclusive strategic cooperation agreement with GlaxoSmithKline.

SBP GROUP (01177) announces that its subsidiary, Jingda Tianqing Pharmaceutical Group Co., Ltd. ("Jingda Tianqing"), has reached an exclusive strategic cooperation agreement with GlaxoSmithKline ("GSK") to accelerate the listing process of bepirovirsen in mainland China. According to the agreement terms, Jingda Tianqing will be responsible for the import, distribution, hospital access, promotion, and non-promotion activities of bepirovirsen in mainland China, and all sales revenue generated by the product will be recognized as Jingda Tianqing's operating income. GSK will continue to act as the Marketing Authorization Holder (MAH) of the drug, responsible for regulatory affairs, quality control, drug vigilance, and global medical strategy. Under the agreement terms, Jingda Tianqing will purchase bepirovirsen from GSK according to agreed supply terms during the initial 5.5-year cooperation period. The cooperation period may be extended by both parties based on mutual agreement. According to the agreement, both parties will also have the opportunity to further collaborate on research and development pipeline assets seeking cooperation opportunities in markets outside of China. This collaboration will support the establishment of a long-term partnership between the two parties and provide a solid foundation for further expanding innovative asset cooperation in the future. This strategic cooperation marks the Group's second high-level recognition from a leading multinational pharmaceutical company (MNC) since the strategic cooperation with Boehringer Ingelheim in April 2024. This demonstrates the Group's exceptional commercial capabilities, extensive market access platform, and comprehensive compliance system. By deepening strategic cooperation with global leading pharmaceutical companies, the Group further consolidates its position as the preferred partner for MNCs in China.